Patents by Inventor Peter Bullock

Peter Bullock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220107180
    Abstract: The present invention relates generally to the field of inertial measurement units (IMU's) and their use in downhole applications and particularly to an IMU configured to allow a calculation of bias or drift, an encoder steering assembly and a drilling target indicator to calculate position of a downhole implement relative to an intended path.
    Type: Application
    Filed: February 11, 2020
    Publication date: April 7, 2022
    Applicant: PRECISION MINING AND DRILLING HOLDINGS PTY LTD
    Inventors: Hayden Scott Thomas WALKER, Peter BULLOCK, David MIITEL
  • Publication number: 20110224182
    Abstract: The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, methods of making the compounds, polymorphic forms of the compounds, the compounds for use as medicaments, and use of the compounds for the manufacture of medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are certain salts of 3-O-(3?,3?-dimethylsuccinyl)betulinic acid, also known as “DSB.” The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus (“HIV”).
    Type: Application
    Filed: July 17, 2009
    Publication date: September 15, 2011
    Applicant: Myriad Pharmaceuticals, Incorporated
    Inventors: Peter Bullock, Theodore J. Nitz, Gary Sweetapple
  • Publication number: 20040147006
    Abstract: Isolated peptides are provided that span the Simian Virus 40 DNA region of the T-ag (or the Bovine Papillomavirus E1 protein) centered on position Thr124 (or Thr102, respectively), which include regulatory motifs, such as the nuclear localization signal (NLS) and the consensus recognition site for cyclin-Cdk kinases. When unphosphorylated, peptides derived from this region bind to DNA and inhibit T-ag assembly. Upon phosphorylation at Thr124 (or Thr102), these peptides neither bind to DNA nor to inhibit T-ag assembly. These forms of regulation of DNA replication and T-ag assembly provide a novel target, and provide screens for anti-viral agents, and for gene therapy.
    Type: Application
    Filed: November 5, 2003
    Publication date: July 29, 2004
    Inventor: Peter Bullock